Advisory Committee Split On Whether FDA Should Draft Nanotech Guidance

FDA currently lacks information to draft effective guidance about the development of nanotechnology derived drug applications, according to a majority of FDA's Pharmaceutical Science and Clinical Pharmacology advisory committee